Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.48 |
| ▸ | MTOR | P42345 | 3/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13891588 | 0.83 | PIK3CA (0.48) | PIK3CAMTORPIK3CBCDK19NTRK1 | |
| SCHEMBL12998313 | 0.83 | PIK3CA (0.48) | PIK3CAMTORPIK3CBCDK19NTRK1 | |
| SCHEMBL19586824 | 0.83 | MAP3K14 (0.45) | MAP3K14PIK3CAMTORPIK3CBCDK19 | |
| SCHEMBL3851193 | 0.83 | MAP3K14 (0.48) | MAP3K14PIK3CAMTORPIK3CBCDK19 | |
| SCHEMBL3847433 | 0.83 | PIK3CA (0.51) | MAP3K14PIK3CAMTORPIK3CBCDK19 | |
| SCHEMBL3847032 | 0.83 | MAP3K14 (0.45) | MAP3K14PIK3CAMTORPIK3CBCDK19 | |
| SCHEMBL3849418 | 0.81 | NR1H4 (0.52) | MAP3K14PIK3CAMTORPIK3CBCDK19 | |
| SCHEMBL3848399 | 0.81 | MAP3K14 (0.43) | MAP3K14PIK3CAMTORPIK3CBCDK19 | |
| SCHEMBL3849684 | 0.80 | RAB9A (0.48) | MAP3K14PIK3CAMTORFLT3EIF2AK4 | |
| SCHEMBL3846525 | 0.80 | MAP3K14 (0.48) | MAP3K14PIK3CAMTORPIK3CBCDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-12-09 | — | — | US | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | PIKFYVE, JAK3, PI4KA | MAP3K14 56/4885PIK3CA 15/4885MTOR 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.